Novo Nordisk CEO spies new pharmaceutical sales model
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, predicts that a new model for pharmaceutical sales will emerge in the long term – a model that can simplify the distribution and pricing of drugs, he tells Danish media Børsen.
by astrid sturlason, translated by catherine brett
The collaboration between public and private pharmaceutical companies, which has been happening during the pandemic, can form the basis of a new business model for pharmaceutical sales in the long term, the CEO of Novo Nordisk Lars Fruergaard Jørgensen tells Danish financial daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
